文献速递膀胱癌与上尿路尿路上皮癌

新辅助化疗联合根治性膀胱切除术与单纯根治性膀胱切除术在无肾积水的临床T2期膀胱癌中的比较

Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
PubMed 文献 · BJU Int · 2020-11-21

该回顾性多中心队列研究纳入619例无术前肾积水的cT2N0M0膀胱癌患者,其中316例接受新辅助化疗(NAC)后根治性膀胱切除术(RC),303例直接行RC。经倾向性评分加权分析,NAC组病理完全缓解率(30% vs 3%)和降期率(55% vs 24%)均显著提高,但中位随访18个月时总生存无显著差异。

要点

  • 无肾积水的cT2N0膀胱癌患者接受NAC可显著提高病理完全缓解率(30% vs 3%)和降期率(55% vs 24%)。
  • NAC是病理完全缓解和降期的独立预测因素。
  • 中位随访18个月,NAC组与直接RC组总生存无显著差异。

核心结论

  • 在无术前肾积水的cT2N0膀胱癌患者中,新辅助化疗可提高病理完全缓解率和降期率,但未观察到总生存获益。

研究设计与样本

  • 回顾性多中心队列研究,纳入619例cT2N0M0膀胱癌无术前肾积水患者,316例接受NAC后RC,303例直接行RC,采用倾向性评分逆概率加权(IPTW)校正选择偏倚。

主要发现

  • IPTW校正后组间标准化差异均<15%。
  • NAC组病理完全缓解(pT0N0)率为30%(94例),直接RC组为3%(9例)。
  • NAC组降期至非肌层浸润性疾病(<pT2N0M0)率为55%(174例),直接RC组为24%(72例)。
  • 多变量分析显示NAC是病理完全缓解和降期的独立预测因素。
  • 中位随访18个月,两组总生存无显著差异。

临床怎么用

  • 对于无肾积水的cT2N0膀胱癌患者,NAC可考虑用于提高病理缓解和降期,但需个体化评估,因总生存获益尚未证实。

局限性

  • 回顾性研究设计,可能存在残余混杂。
  • 中位随访仅18个月,不足以评估总生存差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the efficacy of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in a retrospective multicentre cohort of patients with cT2N0M0 bladder cancer (BCa) without preoperative hydronephrosis. PATIENTS AND METHODS: This was a propensity-based analysis of 619 patients. Of these, 316 were treated with NAC followed by RC and 303 with upfront RC. After multiple imputations, inverse probability of treatment weighting (IPTW) was used to account for potential selection bias. Multivariable logistic regression analysis was performed to evaluate the impact of NAC on pathological complete response and downstaging at RC, while IPTW-adjusted Kaplan-Meier curves and Cox regression models were built to evaluate the impact of NAC on overall survival (OS). RESULTS: After IPTW-adjusted analysis, standardised differences between groups were <15%. A complete response (pT0N0) at final pathology was achieved in 94 (30%) patients receiving NAC and nine (3%) undergoing upfront RC. Downstaging to non-muscle-invasive disease (<pT2N0M0) was observed in 174 (55%) patients after NAC and in 72 (24%) without NAC. On multivariable analysis, NAC was found to be an independent predictor of both pathological complete response and downstaging. No significant difference with respect to OS was observed between groups with a median follow-up of 18 months. CONCLUSIONS: In patients with cT2N0 BCa and no preoperative hydronephrosis, NAC increased the rate of pathological complete response and downstaging.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Soria F, Black PC, Fairey AS, et al. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. BJU Int. 2020. PMID: 33152179. doi:10.1111/bju.15289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。